USFDA successfully concludes inspection at Anacipher CRO - Hyderabad

Indoco Remedies Ltd has announced the successful conclusion of the USFDA inspection at Indoco's Clinical Research Organization - AnaCipher, conducted between 11th - 15th July, 2022.

During the remote record review, the agency did not identify any objectionable conditions and thus, did not have any observations. This inspection was conducted by the Division of New Drug Study Integrity, Office of Study Integrity and Surveillance of USFDA. The scope of the inspection included Bioanalytical phase of multiple studies, of which one was "First to File".

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 384.30 as compared to the previous close of Rs. 388.30. The total number of shares traded during the day was 1631 in over 329 trades.

The stock hit an intraday high of Rs. 394.30 and intraday low of 382.50. The net turnover during the day was Rs. 632226.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 USFDA Inspection CRO AnaCipher